Literature DB >> 25949372

Catheter-related Chryseobacterium meningosepticum bacteraemia in a haemodialysis patient.

Min-Hua Tseng1, Liang-Kuang Diang2, Yi-Chen Su2, Shih-Hua Lin2.   

Abstract

Entities:  

Year:  2009        PMID: 25949372      PMCID: PMC4421377          DOI: 10.1093/ndtplus/sfp080

Source DB:  PubMed          Journal:  NDT Plus        ISSN: 1753-0784


× No keyword cloud information.
Sir, Chryseobacterium meningosepticum (C. meningosepticum), an unusual opportunistic pathogen resistant to multiple antimicrobial agents, was rarely reported to be a cause of bacteraemia in haemodialysis patients. A 77-year-old female with end-stage renal disease was admitted with fever, chills and tenderness on the insertion site of the femoral double-lumen catheter 2 weeks after the start of haemodialysis. Her body temperature was 38.4°C. Erythema and swelling were present around the exit site of the double-lumen catheter. Laboratory evaluation revealed a haemoglobin of 7.6 g/dL and a C-reactive protein of 7.3 mg/dL. A provisional diagnosis of catheter-related bacteraemia was made. The double-lumen vein catheter was removed along with empiric antimicrobial agents with intravenous vancomycin (2 g/week) plus oral rifampin (450 mg/day). Blood cultures grew C. meningosepticum that was resistant to gentamicin, amikacin and all cephalosporins, but only susceptible to ciprofloxacin and vancomycin. Cultures of the exit site and the tip of catheter also grew C. meningosepticum. Despite 1-week antibiotic therapy, blood cultures still grew the same pathogen. At this time, an echocardiogram was normal. The addition of oral ciprofloxacin (250 mg q12 h) to vancomycin for another 2 weeks achieved uneventful recovery without subsequent growth of this organism. Cultures for tap water and dialysate were also negative for this pathogen. Chryseobacterium spp. are of low virulence but give rise to severe infections in neonate and immunocompromised hosts. C. meningosepticum was the most common species of human pathogens. In neonates, C. meningosepticum meningitis is the most common infection, whereas pneumonia and sepsis were the most common infections in adults with impaired immunity [1]. Patients with uraemia are at a risk for C. meningosepticum infection due to their compromised T- and B-cell immunity. To date, there were only few reports regarding C. meningosepticum infections in uraemic patients on dialysis (Table 1) [2-5]. Among 42 episodes in 41 dialysis patients, a majority (37/42, 88%) of episodes were related to peritoneal dialysis (PD) catheter peritonitis and a minority (5/42, 12%) of episodes had bacteraemia in patients on haemodialysis. Initial antibiotics to eradicate C. meningosepticum infections were usually inappropriate, leading to the necessity of removal of the catheter in most patients. Four (4/41, 10%) patients died from C. meningosepticum infection. In C. meningosepticum bacteraemia, the exact port of entry was unknown in three episodes. C. meningosepticum was isolated from sink water in only one episode. Although C. meningosepticum was not identified in tap, tank and dialysis water, in our patient it was also isolated from the exit site and the tip of the double-lumen catheter, suggesting that the port of entry be the disruption of skin integrity by internal placement of the catheter. Our case is the first report of C. meningosepticum bacteraemia associated with catheter-related infection in a haemodialysis patient.
Table 1

Demographic data of the reported patients on dialysis with Chryseobacterium meningosepticum infection

Gender/DialysisAccess forSource ofInitial
ReferenceagemodalitydialysisinfectionConsequenceantibioticsOutcome
[2]F/33CAPDaTenckhoffDialysatePeritonitisNot respondNot remove access,
cathetereffluent(TOB + VAN)survival
[3]F/76CAPDTenckhoffDialysate effluentPeritonitis;Not respondRemove access,
catheterBloodbacteraemia(CTZ + GM + VAN)died
[3]UA/14CAPDTenckhoffBloodSepsisNot respondRemove access,
catheter(NAF + GM)died
[3]F/63CAPDTenckhoffDialysatePeritonitisNot respondRemove access,
cathetereffluent(AZT+ PIP)survival
[3]F/45CAPDTenckhoffDialysatePeritonitisNot respondNot remove access,
cathetereffluent(IMI and TOB)survival
[4]M/54CAPDTenckhoffDialysatePeritonitisNot respondRemove access,
cathetereffluent(CZL + GM)survival
[2]33 casesCAPDTenckhoffDialysatePeritonitisNARemove access:
(30 episodes)cathetereffluentbacteraemiaNA 1 died, 31
HDb (4 episodes)NABloodsurvival.
[2]M/74HDArteriovenousBloodBacteraemia;Not respondRemove access,
graftpurulent(MER)died
pericarditis
[5]M/78CAPDTenckhoffDialysatePeritonitisRespondNot remove access,
cathetereffluent(CIP + RIF)survival
Our caseF/77HDFemoral veinTip of theBacteraemiaNot respondRemove access,
cathetercatheter(VAN + RIF)survival

aCAPD; continuous ambulatory peritoneal dialysis.

bHD: haemodialysis.

NA: not available; TOB: tobramycin; VAN: vancomycin; CTZ: ceftazidime; NAF: nafcillin; AZT: aztreonam; PIP: piperacillin; IMI: imipenem; CZL: cefazolin; GM: gentamicin; MER: meropenem; RIF: rifampin; CIP: ciprofloxacin.

Demographic data of the reported patients on dialysis with Chryseobacterium meningosepticum infection aCAPD; continuous ambulatory peritoneal dialysis. bHD: haemodialysis. NA: not available; TOB: tobramycin; VAN: vancomycin; CTZ: ceftazidime; NAF: nafcillin; AZT: aztreonam; PIP: piperacillin; IMI: imipenem; CZL: cefazolin; GM: gentamicin; MER: meropenem; RIF: rifampin; CIP: ciprofloxacin. Although vancomycin has been previously recommended as the drug of choice for C. meningosepticum infection, recent reports and our case revealed that C. meningosepticum infection failed to respond to vancomycin administration alone [6]. Vancomycin should not be used alone to treat C. meningosepticum infections, especially associated with bacteraemia [6], as shown in the patient. In conclusion, C. meningosepticum should be considered as a causative pathogen of gram-negative bacilli catheter-related bacteremia in haemodialysis patients. Early recognition of this pathogen with appropriate antimicrobial agent administration will avoid the loss of the catheter and even mortality. Conflict of interest statement. None declared.
  6 in total

1.  Flavobacterium group IIb peritonitis in a patient on chronic ambulatory peritoneal dialysis.

Authors:  Z A Akl; L Stern; M F Romagnoli; P Della-Latta
Journal:  Perit Dial Int       Date:  1996 May-Jun       Impact factor: 1.756

2.  Antimicrobial susceptibility of flavobacteria as determined by agar dilution and disk diffusion methods.

Authors:  J C Chang; P R Hsueh; J J Wu; S W Ho; W C Hsieh; K T Luh
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 3.  Flavobacterial peritonitis in patients treated by peritoneal dialysis.

Authors:  Z Korzets; M C Maayan; J Bernheim
Journal:  Nephrol Dial Transplant       Date:  1995       Impact factor: 5.992

4.  Chryseobacterium meningosepticum infection and cardiac tamponade in a long-term hemodialysis patient.

Authors:  Thitima Lothuvachai; Khanchit Likittanasombat; Samaniya Milindankura; Amporn Sakulsaengprapha; Chagriya Kitiyakara
Journal:  Am J Kidney Dis       Date:  2006-10       Impact factor: 8.860

5.  Peritonitis caused by Chryseobacterium meningosepticum in a patient undergoing continuous ambulatory peritoneal dialysis.

Authors:  Vin-Cent Wu; Tun-Jun Tsai; Robert Wang; Po-Ren Hsueh
Journal:  J Formos Med Assoc       Date:  2003-04       Impact factor: 3.282

6.  A Chryseobacterium meningosepticum outbreak in a neonatal ward.

Authors:  Serdal Güngör; Metehan Ozen; Aysehan Akinci; Riza Durmaz
Journal:  Infect Control Hosp Epidemiol       Date:  2003-08       Impact factor: 3.254

  6 in total
  2 in total

1.  Chryseobacterium meningosepticum bacteremia in diabetic nephropathy patient on hemodialysis.

Authors:  M Dias; K Prashant; R Pai; B Scaria
Journal:  Indian J Nephrol       Date:  2010-10

2.  The draft genomes of Elizabethkingia anophelis of equine origin are genetically similar to three isolates from human clinical specimens.

Authors:  William L Johnson; Akhilesh Ramachandran; Nathanial J Torres; Ainsley C Nicholson; Anne M Whitney; Melissa Bell; Aaron Villarma; Ben W Humrighouse; Mili Sheth; Scot E Dowd; John R McQuiston; John E Gustafson
Journal:  PLoS One       Date:  2018-07-19       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.